Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer

Abstract Pegylated liposomal doxorubicin (PLD) is a nano-doxorubicin anticancer agent. It was used as early as 2014 to treat ovarian and breast cancer, multiple myeloma and Kaposi's sarcoma. The 2018 National Comprehensive Cancer Network guidelines listed PLD as first-line chemotherapy for ovar...

Full description

Bibliographic Details
Main Authors: Xin-Ru Li, Xing-Han Cheng, Guo-Nan Zhang, Xiao-Xin Wang, Jian-Ming Huang
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Journal of Ovarian Research
Subjects:
Pegylated liposomal doxorubicin
Cardiotoxicity
High-risk factors
Cardiac function test
Ovarian cancer
Online Access:https://doi.org/10.1186/s13048-022-01029-6

Internet

https://doi.org/10.1186/s13048-022-01029-6

Similar Items